Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
In patients with advanced kidney disease (AKD) and atrial fibrillation (AF), the safety and efficacy of direct oral anticoagulants (DOACs) have not yet been thoroughly proven. Goals to ascertain the safety and efficacy of combined or targeted DOACs in relation to warfarin in patients with AKD and AF. Techniques Retrospective identification was conducted in a Hospital for patients with AF and AKD (estimated glomerular filtration rate < 30mL/min) who were treated with warfarin or DOAC between June 2013 and December 2022. Major bleeding and hospitalizations for stroke/systemic embolism were the main consequences. Any bleeding and any ischaemia were considered secondary outcomes. Previously, prescriptions for dabigatran, rivaroxaban, apixaban and edoxaban were written in 2012, 2013, 2015 and 2017, respectively. Following the introduction of DOACs, the proportion of patients using warfarin dropped significantly over time (100% in 2011 and 20% in 2020). Similarly, following a sharp increase to a peak of 30.2% in 2013 and 35.4% in 2015, respectively, a downward tendency is seen with dabigatran and rivaroxaban. DOACs were associated with a decreased risk of ischaemic events in individuals with AF and AKD, while apixaban was associated with a lower risk of both ischaemia and bleeding overall compared to warfarin.
How to cite this article:
Megha R. Raju and M.K. Suresh. Comparative Efficacy of Direct Oral Anticoagulants vs. Warfarin in Atrial Fibrillation.
DOI: https://doi.org/10.36478/10.36478/makrjms.2024.11.33.38
URL: https://www.makhillpublications.co/view-article/1815-9346/10.36478/makrjms.2024.11.33.38